A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Palmoplantar Pustulosis Psoriasis Area and Severity Index (ppPASI) at 16 Weeks of Treatment, Compared to Placebo, and to Assess Long-term Safety, Tolerability, and Efficacy in Subjects With Moderate to Severe Chronic Palmoplantar Pustular Psoriasis - Amended With an Optional Extension Treatment Period of up to a Total of 148 Weeks
Latest Information Update: 13 Dec 2022
At a glance
- Drugs Secukinumab (Primary)
- Indications Pustular psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 18 Jun 2020 Results assessing efficacy and safety of secukinumab in moderate to severe palmoplantar pustular psoriasis over 148 weeks, published in the Journal of the American Academy of Dermatology.
- 01 Feb 2019 Primary endpoint (Percentage of Participants With ppPASI 75 Response at Week 16 (Period 1)) has not been met, as per results published in the Journal of the American Academy of Dermatology.
- 01 Feb 2019 Results published in the Journal of the American Academy of Dermatology